Log in

NextCure Stock Price, Forecast & Analysis (NASDAQ:NXTC)

$36.00
-0.35 (-0.96 %)
(As of 11/20/2019 01:24 AM ET)
Today's Range
$35.22
Now: $36.00
$36.93
50-Day Range
$25.43
MA: $35.20
$82.89
52-Week Range
$13.86
Now: $36.00
$109.00
Volume473,900 shs
Average Volume223,759 shs
Market Capitalization$819.14 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
There is no company description available for NextCure Inc.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NXTC
CUSIPN/A
CIKN/A
Phone240-399-4900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-22,800,000.00

Miscellaneous

EmployeesN/A
Market Cap$819.14 million
Next Earnings Date2/11/2020 (Estimated)
OptionableNot Optionable

Receive NXTC News and Ratings via Email

Sign-up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter.


NextCure (NASDAQ:NXTC) Frequently Asked Questions

What is NextCure's stock symbol?

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

How were NextCure's earnings last quarter?

NextCure Inc (NASDAQ:NXTC) issued its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.02. The firm had revenue of $1.58 million for the quarter, compared to analyst estimates of $1.50 million. View NextCure's Earnings History.

When is NextCure's next earnings date?

NextCure is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for NextCure.

What price target have analysts set for NXTC?

3 brokers have issued 1 year target prices for NextCure's stock. Their forecasts range from $52.00 to $95.00. On average, they anticipate NextCure's stock price to reach $78.67 in the next year. This suggests a possible upside of 118.5% from the stock's current price. View Analyst Price Targets for NextCure.

What is the consensus analysts' recommendation for NextCure?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NextCure.

Has NextCure been receiving favorable news coverage?

News headlines about NXTC stock have trended somewhat positive recently, InfoTrie reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. NextCure earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for NextCure.

Are investors shorting NextCure?

NextCure saw a increase in short interest in October. As of October 15th, there was short interest totalling 515,300 shares, an increase of 6.9% from the September 15th total of 482,000 shares. Based on an average daily volume of 88,400 shares, the short-interest ratio is currently 5.8 days. Approximately 4.2% of the shares of the company are short sold. View NextCure's Current Options Chain.

Who are some of NextCure's key competitors?

What other stocks do shareholders of NextCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include Alibaba Group (BABA), Home Depot (HD), CVS Health (CVS), Honeywell International (HON), Thermo Fisher Scientific (TMO), Amgen (AMGN), Cisco Systems (CSCO), NVIDIA (NVDA), Johnson & Johnson (JNJ) and Mcdonald's (MCD).

When did NextCure IPO?

(NXTC) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO.

When did the company's lock-up period expire?

NextCure's lock-up period expired on Tuesday, November 5th. NextCure had issued 5,000,000 shares in its IPO on May 9th. The total size of the offering was $75,000,000 based on an initial share price of $15.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period.

Who are NextCure's major shareholders?

NextCure's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Matthews International Capital Management LLC (1.84%) and Strs Ohio (0.03%). Company insiders that own NextCure stock include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan. View Institutional Ownership Trends for NextCure.

Which institutional investors are selling NextCure stock?

NXTC stock was sold by a variety of institutional investors in the last quarter, including Matthews International Capital Management LLC. View Insider Buying and Selling for NextCure.

Which institutional investors are buying NextCure stock?

NXTC stock was acquired by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have bought NextCure stock in the last two years include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan. View Insider Buying and Selling for NextCure.

How do I buy shares of NextCure?

Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is NextCure's stock price today?

One share of NXTC stock can currently be purchased for approximately $36.00.

How big of a company is NextCure?

NextCure has a market capitalization of $819.14 million. View Additional Information About NextCure.

What is NextCure's official website?

The official website for NextCure is http://www.nextcure.com/.

How can I contact NextCure?

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected]


MarketBeat Community Rating for NextCure (NASDAQ NXTC)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  27 (Vote Outperform)
Underperform Votes:  19 (Vote Underperform)
Total Votes:  46
MarketBeat's community ratings are surveys of what our community members think about NextCure and other stocks. Vote "Outperform" if you believe NXTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NXTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2019 by MarketBeat.com Staff

Featured Article: Support Level

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel